Evidence map›Paper›PMID 36776309›Full record

ReviewFrontiers in oncology2023

MRI-LINAC: A transformative technology in radiation oncology.

John Ng, Fabiana Gregucci, Ryan T Pennell, Himanshu Nagar, Encouse B Golden, Jonathan P S Knisely, Nicholas J Sanfilippo, Silvia C Formenti

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Lanthanide Nanotheranostics in Radiotherapy.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

John NgDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, United States.
Fabiana GregucciDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, United States.
Ryan T PennellDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, United States.
Himanshu NagarDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, United States.
Encouse B GoldenDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, United States.
Jonathan P S KniselyDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, United States.
Nicholas J SanfilippoDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, United States.
Silvia C FormentiDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in radiotherapy technologies have enabled more precise target guidance, improved treatment verification, and greater control and versatility in radiation delivery. Amongst the recent novel technologies, Magnetic Resonance Imaging (MRI) guided radiotherapy (MRgRT) may hold the greatest potential to improve the therapeutic gains of image-guided delivery of radiation dose. The ability of the MRI linear accelerator (LINAC) to image tumors and organs with on-table MRI, to manage organ motion and dose delivery in real-time, and to adapt the radiotherapy plan on the day of treatment while the patient is on the table are major advances relative to current conventional radiation treatments. These advanced techniques demand efficient coordination and communication between members of the treatment team. MRgRT could fundamentally transform the radiotherapy delivery process within radiation oncology centers through the reorganization of the patient and treatment team workflow process. However, the MRgRT technology currently is limited by accessibility due to the cost of capital investment and the time and personnel allocation needed for each fractional treatment and the unclear clinical benefit compared to conventional radiotherapy platforms. As the technology evolves and becomes more widely available, we present the case that MRgRT has the potential to become a widely utilized treatment platform and transform the radiation oncology treatment process just as earlier disruptive radiation therapy technologies have done.

Indexed as

external beam radiotherapyimage-guided radiation therapymedical physicsMR-guided radiation therapyMRIradiation therapy technology

Identifiers

PMID36776309
PMCPMC9911688

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.